Use of Ephedra-containing products and risk for hemorrhagic stroke.
This case-control study examined the association between Ephedra use and risk for hemorrhagic stroke. For use of Ephedra at any dose during the 3 days before the stroke, the adjusted OR was 1.00 (95% CI 0.32 to 3.11). For daily doses of < or =32 mg/day, the OR was 0.13 (95% CI 0.01 to 1.54), and for >32 mg/day, the OR was 3.59 (95% CI 0.70 to 18.35). Ephedra is not associated with increased risk for hemorrhagic stroke, except possibly at higher doses.
Morgenstern
L B
LB
Stroke Program, Department of Neurology, University of Texas at Houston, USA. lmorgens@umich.edu
Viscoli
C M
CM
Kernan
W N
WN
Brass
L M
LM
Broderick
J P
JP
Feldmann
E
E
Wilterdink
J L
JL
Brott
T
T
Horwitz
R I
RI
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D015984:Causality; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D029789:Ephedra / Q000009:adverse effects*; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced* / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010665:Phenylpropanolamine / Q000009:adverse effects; D008517:Phytotherapy / Q000009:adverse effects*; D028321:Plant Preparations / Q000009:adverse effects*; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
D028321:Plant Preparations; D010665:Phenylpropanolamine